Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3054572 | 0.88 | METAP2 (0.34) | ENPP1METAP2METAP1 | |
| SCHEMBL235437 | 0.76 | CACNA1H (0.41) | ENPP1METAP2METAP1 | |
| SCHEMBL3044434 | 0.75 | METAP2 (0.35) | ENPP1METAP2METAP1 | |
| SCHEMBL9569994 | 0.71 | METAP2 (0.42) | ENPP1METAP2METAP1 | |
| SCHEMBL6485 | 0.71 | METAP2 (0.42) | ENPP1METAP2METAP1 | |
| SCHEMBL5358317 | 0.71 | METAP2 (0.38) | ENPP1METAP2METAP1 | |
| SCHEMBL7073073 | 0.69 | RAD52 (0.42) | ENPP1METAP2METAP1POLB | |
| SCHEMBL4955472 | 0.68 | METAP2 (0.42) | ENPP1METAP2METAP1 | |
| SCHEMBL30884953 | 0.68 | METAP2 (0.42) | ENPP1METAP2METAP1 | |
| SCHEMBL29208955 | 0.68 | METAP2 (0.42) | ENPP1METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2223927-B1 | Salts of a phosphonic acid based prodrug of PMEA | METABASIS THERAPEUTICS INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2223927-A2 | Cyclic phosphonic acid based prodrugs of PMEA and its analogues | Metabasis Therapeutics, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1532157-A4 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | METABASIS THERAPEUTICS INC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7214668-B2 | Phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1532157-A2 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | Metabasis Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004037161-A2 | CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES | METABASIS THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | MTAP, PNP, MPO | ENPP1 13/4885METAP2 113/4885METAP1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.